Bridge Biosciences

BridgeBio Pharma is a commercial-stage biopharmaceutical company focused on developing breakthrough medicines for genetic diseases and cancers with clear genetic drivers. The company utilizes a unique hub-and-spoke business model, where a centralized team of experts identifies promising early-stage research and develops it through specialized subsidiary companies. BridgeBio's diverse pipeline includes treatments for transthyretin amyloidosis (ATTR), achondroplasia, and congenital adrenal hyperplasia, among others. With the FDA approval of acoramidis for ATTR-CM, the company has transitioned into a fully integrated commercial entity. BridgeBio continues to leverage its platform to rapidly advance a broad portfolio of targeted therapies from discovery through global commercialization.